AU Patent

AU2004261779B2 — Use of RNAi inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer

Assigned to University of Sheffield · Expires 2008-07-24 · 18y expired

What this patent protects

The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

USPTO Abstract

The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.

Drugs covered by this patent

Patent Metadata

Patent number
AU2004261779B2
Jurisdiction
AU
Classification
Expires
2008-07-24
Drug substance claim
No
Drug product claim
No
Assignee
University of Sheffield
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.